drugset / Trial / NCT01238575
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Phase 4
Completed
62 enrolled
Yale University
Emory University · collabMassachusetts General Hospital · collabNational Institute of Mental Health (NIMH) · collabSeattle Children's Hospital · collabUniversity of California, Los Angeles · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself or in combination with methylphenidate (also known as Ritalin) is helpful for treating hyperactivity in children and adolescents with a Pervasive Developmental Disorders (PDDs).
Timeline
- Start
- 2011-12
- Primary completion
- 2014-03
- Completion
- 2014-03
Publications
- Background Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Posey D, Young C, Shah B, Ghuman J, Ritz L, Vitiello B. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006 Oct;16(5):589-98. doi: 10.1089/cap.2006.16.589.
- Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guanfacine | Small molecule | 1 mg | — |
| Subject | Guanfacine | Small molecule | 4 mg | — |